VIDEO: IMpower010 results 'first demonstration' of benefits from atezolizumab in certain patients with lung cancer
In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the IMpower010 study presented at ESMO 2021.
The study assessed the use of adjuvant atezolizumab among patients with surgically resected NSCLC lung cancer who had undergone adjuvant chemotherapy.
Jänne explained that results from the study were presented earlier this year at ASCO 2021 and that “there was more nuance on the biomarkers, specifically the PDL-1 expression,” in the findings presented at ESMO 2021.
According to Jänne, the findings “demonstrated that the patients that derive the greatest benefit are those that have high PD-L1 expression, i.e., greater than 50%,” which he noted is also seen among patients with advanced disease.
“We’re looking forward to how this develops further as we learn more about the study, and ultimately, of course, hopefully learn whether the improvement in disease-free survival translates into an improvement in overall survival — meaning are we able to cure more individuals with early-stage lung cancer who receive surgery, chemotherapy and atezolizumab,” Jänne said. “We eagerly await to see those results, but this was really the first demonstration that it is beneficial.”
Collapse
Read more about